Ramezn Eskander News Today

Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status.

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Treatments for advanced endometrial cancer have progressed and improved with the use of immunotherapy with chemotherapy.

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 -- Myriad Genetics, Inc. , a leader in genetic testing... | June 11, 2023

24.05.2023 - Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, ...

The addition of pembrolizumab to paclitaxel plus carboplatin is associated with longer progression-free survival for patients with advanced or recurrent endometrial cancer.

Ramez N. Eskander, MD, highlights the potential implications of the NRG GY018 trial as well as safety and efficacy results from the trial.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.